Andrew Pusar, a partner in Goodwin’s Technology Companies and Life Sciences group, concentrates in general corporate and securities law and has significant experience in capital markets transactions, mergers and acquisitions, venture capital financings, SEC compliance and corporate governance. Andrew represents public and private emerging growth technology and life science companies as well as venture capital funds and investment banks focusing on technology and life science companies. He has experience advising companies through every stage of the corporate life cycle – from initial financing through successful initial public offering or acquisition.
Representative Matters
- Has represented numerous venture capital firms in early stage seed financings through late stage growth equity financings. Such firms include Benchmark, Felicis, Greycroft, Lightspeed, Redpoint, and Archerman Capital, among others
- Jobber in its Series D financing led by General Atlantic
- Sesame in its Series B financing led by GV
- CareSyntax in its Series C financing led by PFM, Intel and Blackrock
- Atom Finance in its Series B financing led by SoftBank
- Commerce Layer in its Series B financing led by Coatue and Benchmark
- Goldbelly in its Series C financing led by Spectrum Equity and Intel Capital
- Maximus in its joint venture with IMAX Corporation
- Toast in its Series F financing with participation by Bessemer Venture Partners, TPG, Greenoaks Capital and Tiger Global Management.
- SmileDirectClub in its preferred equity financing with participation from Clayton, Dubilier & Rice, Kleiner Perkins and Spark Capital
- Kensho Technologies in its Series B financing with participation by S&P, Goldman Sachs, General Catalyst, Morgan Stanley and JPMorgan
- Codiak BioSciences in its Series C financing with participation by ARCH Venture Partners, Flagship Pioneering and Fidelity Management and Research Company
- Glossier in its Series B financing led by Institutional Venture Partners, with participation from Index Ventures, Thrive Capital and Forerunner Ventures
- Anchor FM in its Series A financing led by Google Ventures and Accel
- Precision Biologics in its Series A financing by an affiliate of NantWorks
- Orchard Platform in its Series B financing led by Thrive Capital, Spark Capital and Canaan Partners
- Even Financial in its Series A financing with participation by GreatPoint Ventures, Goldman Sachs PSI, Canaan Partners, Fidelity, Lerer Hippeau and AMEX
- EasyKnock in its acquisition of Ribbon
- Even Financial in its sale to MoneyLion
- Pond5 in its sale to ShutterStock
- Bbot in its sale to DoorDash
- The Infatuation in its sale to JPMorgan Chase
- Phreesia in its acquisition of Insignia Health/li>
- Updater in its acquisition of Dolly
- Amper Music in its sale to Shutterstock
- StellaService in its acquisition by Medallia
- Even Financial in its acquisition of LeapLife
- MediaMorph in its sale to Whip Media Group
- Anchor FM in its sale to Spotify
- 7Park Data in its sale to Vista Equity Partners
- Kensho Technologies in its sale to S&P Global
- Interactions in its acquisition of Digital Roots
- Orchard Platform in its sale of substantially all of its assets to Kabbage, Inc.
- Nalari Health in its sale to BehaveCare
- Catheter Connections in its sale to Merit Medical Systems
- Toast, Inc. in its initial public offering
- Phreesia, Inc. in its initial public offering and its primary and secondary follow-on offerings
- CRISPR Therapeutics AG in its initial public offering
- Represented the underwriters in Olo’s initial public offering
- Represented the underwriters, including RBC, in Altair Engineering’s initial public offering and follow-on offering
- Represented investment bankers, including Cowen, in G1 Therapeutics’ initial public offering and follow-on offering
- Represented William Blair in follow-on offerings by USA Technologies
- Represented Cowen in follow-on offerings by Albireo Pharma
- Represented the underwriter in Oncobiologics’ initial public offering
- Represented the underwriters in a follow-on offering by Syndax Pharmaceuticals
- Represented Cowen and Company in multiple “At-the-Market” transactions
Professional Activities
Andrew is a frequent lecturer at Columbia Business School, Columbia Law School and Cornell Tech on venture financings and other elements of start-up law. He also holds office hours for emerging companies working with the New York Angels, which is one of the longest-running active angel groups in New York City. Andrew is also an active leader at Goodwin, committed to global initiatives supporting practice management, and associate development efforts rooted in the firm’s core values. He frequently participates in Goodwin’s recruiting, training and mentoring efforts which focus on the importance of diversity and inclusion.
Professional Experience
Prior to joining Goodwin, Andrew was an associate in the New York office of Davis Polk & Wardwell LLP.
Credentials
Education
JD2012
Columbia Law School
(Harlan Fiske Stone scholar)
BA2009
Harvard University
Admissions
Bars
- New York
- New Jersey